Page 3 - Comp Eff News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Daiichi Sankyo Company, Limited: Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast Cancer
Daiichi Sankyo Company, Limited
(hereafter, Daiichi Sankyo) and AstraZeneca s trastuzumab deruxtecan has been recommended for conditional marketing authorization in the European Union (EU) as monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens.
In Europe, approximately 520,000 cases of breast cancer in women are diagnosed annually, with roughly one in five cases being HER2 positive.
1,2 The impact of the disease is significant, with breast cancer responsible for more than 137,000 deaths per year. ....

United States , Masashi Kawase , Daiichi Sankyo , Daiichi Sankyo Europe Gmb , Trastuzumab Deruxtecan , Melo Gagliato , Plexxikon Inc , Daiichi Sankyo Inc , Daiichi Sankyo Company , Oncology Development , World Health Organization , European Commission , Drug Administration , Trastuzumab Deruxtecan Clinical Development Program , Daiichi Sankyo Co Ltd , European Union , Daiichi Sankyo Group , Committee For Medicinal Products Human Use , National Comprehensive Cancer Network , Sankyo Company , Medicinal Products , Human Use , Thenew England Journal , Antonio Breast Cancer Symposium , Gilles Gallant , Senior Vice President ,